Long-Term Medication Profiles in Parkinson's Disease under Subthalamic Deep Brain Stimulation: A Controlled Study.
deep brain stimulation (DBS)
levodopa equivalent daily dose (LEDD)
medication
nucleus subthalamicus (STN)
Journal
Movement disorders clinical practice
ISSN: 2330-1619
Titre abrégé: Mov Disord Clin Pract
Pays: United States
ID NLM: 101630279
Informations de publication
Date de publication:
07 May 2024
07 May 2024
Historique:
revised:
08
04
2024
received:
05
12
2023
accepted:
18
04
2024
medline:
8
5
2024
pubmed:
8
5
2024
entrez:
8
5
2024
Statut:
aheadofprint
Résumé
Subthalamic deep brain stimulation (STN-DBS) reduces antiparkinsonian medications in Parkinson's disease (PD) compared with the preoperative state. Longitudinal and comparative studies on this effect are lacking. To compare longitudinal trajectories of antiparkinsonian medication in STN-DBS treated patients to non-surgically treated control patients. We collected retrospective information on antiparkinsonian medication from PD patients that underwent subthalamic DBS between 1999 and 2010 and control PD patients similar in age at onset and baseline, sex-distribution, and comorbidities. In 74 DBS patients levodopa-equivalent daily dose (LEDD) were reduced by 33.9-56.0% in relation to the preoperative baseline over the 14-year observational period. In 61 control patients LEDDs increased over approximately 10 years, causing a significant divergence between groups. The largest difference amongst single drug-classes was observed for dopamine agonists. In PD patients, chronic STN-DBS was associated with a lower LEDD compared with control patients over 14 years.
Sections du résumé
BACKGROUND
BACKGROUND
Subthalamic deep brain stimulation (STN-DBS) reduces antiparkinsonian medications in Parkinson's disease (PD) compared with the preoperative state. Longitudinal and comparative studies on this effect are lacking.
OBJECTIVE
OBJECTIVE
To compare longitudinal trajectories of antiparkinsonian medication in STN-DBS treated patients to non-surgically treated control patients.
METHODS
METHODS
We collected retrospective information on antiparkinsonian medication from PD patients that underwent subthalamic DBS between 1999 and 2010 and control PD patients similar in age at onset and baseline, sex-distribution, and comorbidities.
RESULTS
RESULTS
In 74 DBS patients levodopa-equivalent daily dose (LEDD) were reduced by 33.9-56.0% in relation to the preoperative baseline over the 14-year observational period. In 61 control patients LEDDs increased over approximately 10 years, causing a significant divergence between groups. The largest difference amongst single drug-classes was observed for dopamine agonists.
CONCLUSION
CONCLUSIONS
In PD patients, chronic STN-DBS was associated with a lower LEDD compared with control patients over 14 years.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. Movement Disorders Clinical Practice published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Références
Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. Nat Rev Dis Prim 2017;3:1–21.
Poewe W, Mahlknecht P. Pharmacologic treatment of motor symptoms associated with Parkinson disease. Neurol Clin 2020;38:255–267. http://www.ncbi.nlm.nih.gov/pubmed/32279709.
Macleod AD, Taylor KSM, Counsell CE. Mortality in Parkinson's disease: a systematic review and meta‐analysis. Mov Disord 2014;29:1615–1622. http://www.ncbi.nlm.nih.gov/pubmed/24821648.
Verschuur CVM, Suwijn SR, Boel JA, et al. Randomized delayed‐start trial of levodopa in Parkinson's disease. N Engl J Med [online serial] 2019;380:315–324. http://www.ncbi.nlm.nih.gov/pubmed/30673543.
Deuschl G, Agid Y. Subthalamic neurostimulation for Parkinson's disease with early fluctuations: balancing the risks and benefits. Lancet Neurol 2013;12:1025–1034.
Mahlknecht P, Foltynie T, Limousin P, Poewe W. How does deep brain stimulation change the course of Parkinson's disease? Mov Disord 2022;37:1581–1592. http://www.ncbi.nlm.nih.gov/pubmed/35560443.
Ng JH, See AAQ, Xu Z, King NKK. Longitudinal medication profile and cost savings in Parkinson's disease patients after bilateral subthalamic nucleus deep brain stimulation. J Neurol 2020;267:2443–2454. https://doi.org/10.1007/s00415-020-09741-3.
Lau B, Meier N, Serra G, et al. Axial symptoms predict mortality in patients with Parkinson disease and subthalamic stimulation. Neurology 2019;92:e2559–e2570. http://www.ncbi.nlm.nih.gov/pubmed/31043471.
Rizzone MG, Fasano A, Daniele A, et al. Long‐term outcome of subthalamic nucleus DBS in Parkinson's disease: from the advanced phase towards the late stage of the disease? Park Relat Disord 2014;20:376–381. https://doi.org/10.1016/j.parkreldis.2014.01.012.
Zibetti M, Merola A, Rizzi L, et al. Beyond nine years of continuous subthalamic nucleus deep brain stimulation in Parkinson's disease. Mov Disord 2011;26:2327–2334. http://www.ncbi.nlm.nih.gov/pubmed/22012750.
Castrioto A, Lozano AM, Poon Y‐Y, Lang AE, Fallis M, Moro E. Ten‐year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. Arch Neurol 2011;68:1550–1556. http://www.ncbi.nlm.nih.gov/pubmed/21825213.
Fasano A, Romito LM, Daniele A, Piano C, Zinno M, Bentivoglio AR, Albanese A. Motor and cognitive outcome in patients with Parkinson's disease 8 years after subthalamic implants. Brain 2010;133:2664–2676. http://www.ncbi.nlm.nih.gov/pubmed/20802207.
Mahlknecht P, Peball M, Mair K, et al. Has deep brain stimulation changed the very long‐term outcome of Parkinson's disease? A controlled longitudinal study. Mov Disord Clin Pract 2020;7:782–787. http://www.ncbi.nlm.nih.gov/pubmed/33033735.
Limousin P, Foltynie T. Long‐term outcomes of deep brain stimulation in Parkinson disease. Nat Rev Neurol 2019;15:234–242. https://doi.org/10.1038/s41582-019-0145-9.
Peralta CM, Frauscher B, Seppi K, Wolf E, Wenning GK, Högl B, Poewe W. Restless legs syndrome in Parkinson's disease. Mov Disord 2009;24:2076–2080. http://www.ncbi.nlm.nih.gov/pubmed/19691124.
Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010;25:2649–2653.
Coelho M, Ferreira JJ. Late‐stage Parkinson disease. Nat Rev Neurol 2012;8:435–442. https://doi.org/10.1038/nrneurol.2012.126.
Kieburtz K, Tilley BC, Elm JJ, et al. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA 2015;313:584–593. http://www.ncbi.nlm.nih.gov/pubmed/25668262.
Parkinson Study Group STEADY‐PD III Investigators. Isradipine versus placebo in early Parkinson disease: a randomized trial. Ann Intern Med 2020;172:591–598. http://www.ncbi.nlm.nih.gov/pubmed/32227247.
Gonzalez‐Robles C, Weil RS, van Wamelen D, et al. Outcome measures for disease‐modifying trials in Parkinson's disease: consensus paper by the EJS ACT‐PD multi‐arm multi‐stage trial initiative. J Parkinsons Dis 2023;13:1011–1033. http://www.ncbi.nlm.nih.gov/pubmed/37545260.
Alexoudi A, Shalash A, Knudsen K, Witt K, Mehdorn M, Volkmann J, Deuschl G. The medical treatment of patients with Parkinson's disease receiving subthalamic neurostimulation. Parkinsonism Relat Disord 2015;21:555–560; discussion 555. https://doi.org/10.1016/j.parkreldis.2015.03.003.
Corvol J‐C, Artaud F, Cormier‐Dequaire F, et al. Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology 2018;91:e189–e201. http://www.ncbi.nlm.nih.gov/pubmed/29925549.
Lang S, Vetkas A, Conner C, Kalia LV, Lozano AM, Kalia SK. Predictors of future deep brain stimulation surgery in de novo Parkinson's disease. Mov Disord Clin Pract 2023;10(6):933–942. https://doi.org/10.1002/mdc3.13747.